000 | 01853 a2200565 4500 | ||
---|---|---|---|
005 | 20250517132642.0 | ||
264 | 0 | _c20180221 | |
008 | 201802s 0 0 eng d | ||
022 | _a1949-2553 | ||
024 | 7 |
_a10.18632/oncotarget.12067 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aLiu, Zhong | |
245 | 0 | 0 |
_aBinding of human recombinant mutant soluble ectodomain of FGFR2IIIc to c subtype of FGFRs: implications for anticancer activity. _h[electronic resource] |
260 |
_bOncotarget _cOct 2016 |
||
300 |
_a68473-68488 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aApoptosis _xdrug effects |
650 | 0 | 4 |
_aBinding Sites _xgenetics |
650 | 0 | 4 | _aCell Line, Tumor |
650 | 0 | 4 | _aChick Embryo |
650 | 0 | 4 |
_aChorioallantoic Membrane _xblood supply |
650 | 0 | 4 |
_aFibroblast Growth Factor 2 _xchemistry |
650 | 0 | 4 | _aHEK293 Cells |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMCF-7 Cells |
650 | 0 | 4 | _aMice, Nude |
650 | 0 | 4 | _aMolecular Dynamics Simulation |
650 | 0 | 4 | _aMutation |
650 | 0 | 4 |
_aNeoplasms _xblood supply |
650 | 0 | 4 |
_aNeovascularization, Pathologic _xgenetics |
650 | 0 | 4 |
_aProtein Binding _xdrug effects |
650 | 0 | 4 |
_aProtein Isoforms _xchemistry |
650 | 0 | 4 |
_aReceptor, Fibroblast Growth Factor, Type 2 _xchemistry |
650 | 0 | 4 |
_aRecombinant Proteins _xchemistry |
650 | 0 | 4 | _aTransplantation, Heterologous |
700 | 1 | _aLiu, Ge | |
700 | 1 | _aZhang, Guang-Lin | |
700 | 1 | _aLi, Jun | |
700 | 1 | _aHe, Yan-Qing | |
700 | 1 | _aZhang, Shu-Shu | |
700 | 1 | _aWang, Yi | |
700 | 1 | _aHe, Wei-Yi | |
700 | 1 | _aCheng, Guo-Hua | |
700 | 1 | _aYang, Xuesong | |
700 | 1 | _aXu, Jun | |
700 | 1 | _aWang, Ju | |
773 | 0 |
_tOncotarget _gvol. 7 _gno. 42 _gp. 68473-68488 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.18632/oncotarget.12067 _zAvailable from publisher's website |
999 |
_c26749714 _d26749714 |